Evidence map›Paper›PMID 40159516›Full record

ArticleNPJ digital medicine2025

Deep learning-based mobile application for efficient eyelid tumor recognition in clinical images.

Shiqi Hui, Jing Xie, Li Dong, Li Wei, Weiwei Dai, Dongmei Li

Abstract read
In one paragraph

Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shiqi HuiBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Jing XieInstitute of Digital Ophthalmology and Visual Science, Changsha Aier Eye Hospital, Changsha, Hunan, China.
Li DongBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Li WeiMingsii Co., Ltd, Beijing, China.
Weiwei DaiInstitute of Digital Ophthalmology and Visual Science, Changsha Aier Eye Hospital, Changsha, Hunan, China. daiweiwei@aierchina.com.
Dongmei LiBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. ldmlily@x263.net.

Funding

National Natural Science Foundation of China 82071005Sanming Project of Medicine in Shenzen Municipality No.SZSM202311018Science and Technology Innovation program of Hunan Province, China 2024RC3249
6 · The paper itself

Abstract

Early detection, regular monitoring of eyelid tumors and post-surgery recurrence monitoring are crucial for patients. However, frequent hospital visits are burdensome for patients with poor medical conditions. This study validates a novel deep learning-based mobile application, based on YOLOv5 and Efficient-Net v2-B architectures, for self-diagnosing eyelid tumors, enabling improved health support systems for such patients. 1195 preprocessed clinical ocular photographs and biopsy results were collected for model training. The best-performing model was chosen and converted into a smartphone-based application, then further evaluated based on external validation dataset, achieved 0.921 accuracy for triple classification outcomes (benign/malignant eyelid tumors or normal eye), generally superior to that of general physicians, resident doctors, and ophthalmology specialists. Intelligent Eyelid Tumor Screening application exhibited a straightforward detection process, user-friendly interface and treatment recommendation scheme, provides preliminary evidence for recognizing eyelid tumors and could be used by healthcare professionals, patients and caregivers for detection and monitoring purposes.

Identifiers

PMID40159516
PMCPMC11955516

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.